Savara Inc business relationships
Companies named in Savara Inc’s 10-K filed 2026-03-13, and public companies whose annual reports name Savara Inc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 57 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Savara Inc’s annual report 4
“However, there is still limited information available on the long-term safety of inhaled GM-CSF.” SEC filing
“Under the terms of the PARI License Agreement, Savara is not permitted to work with third parties to develop any inhalation device or nebulizer for the pulmonary delivery of a pharmaceutical product containing GM-CSF as the sole active ingredient.” SEC filing
“The drug substance in Leukine, sargramostim, has been used in a nonclinical research project conducted by NIH/TRND in collaboration with the University of Cincinnati College of Medicine on the potential application of inhaled GM-CSF as a treatment for autoimmune PAP.” SEC filing
“All clinical and nonclinical trials to-date have used material sourced from GEMA Biotech S.A. ("GEMA") in Buenos Aires, Argentina and validation activities are ongoing to prepare for commercial manufacturing.” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms